Trials / Unknown
UnknownNCT05471440
SWITCH ON: Analysing the Immunogenicity of Additional Booster Vaccinations in HCW
SWITCH ON: Analysing the Immunogenicity of Additional Booster Vaccinations in Healthcare Workers. A Multicenter, Randomised, Controlled Trial
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 431 (actual)
- Sponsor
- Erasmus Medical Center · Academic / Other
- Sex
- All
- Age
- 18 Years – 67 Years
- Healthy volunteers
- Accepted
Summary
Eighty percent of the Dutch population has completed a primary COVID-19 vaccination regimen, and 60% of the population received a booster vaccination. Waning immunity, combined with the emergence of antigenically distinct SARS-CoV-2 variants, has led to the consideration of additional booster vaccinations in the Dutch population by autumn 2022. However, despite efforts of the Dutch policymakers, the public's willingness to repeatedly receive COVID-19 booster vaccinations is declining. This is mainly due to a reduced burden of disease by COVID-19, fewer hospitalizations, and fewer deaths. However, population immunity might be one of the major factors responsible for this reduced burden of disease, possibly emphasizing the need for booster vaccinations. In this proposal we will address an important question asked by policymakers: "Are booster vaccinations in autumn recommended for the healthy population?"
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Direct boost mRNA | Participants will be boosted with a covid-19 vaccin after priming with mRNA |
| DRUG | Direct boost adeno | Participants will be boosted with a covid-19 vaccin after priming with adeno |
| DRUG | Post-poned boost mRNA | Participants will be boosted with a covid-19 vaccin after priming with mRNA |
| DRUG | Post-poned boost adeno | Participants will be boosted with a covid-19 vaccin after priming with adeno |
Timeline
- Start date
- 2022-08-20
- Primary completion
- 2022-09-15
- Completion
- 2023-08-30
- First posted
- 2022-07-22
- Last updated
- 2023-02-15
Locations
4 sites across 1 country: Netherlands
Source: ClinicalTrials.gov record NCT05471440. Inclusion in this directory is not an endorsement.